Shopping Cart
- Remove All
- Your shopping cart is currently empty
DS-1040 Tosylate is an oral active, selective thrombolytic inhibitor with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa, is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases[1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $119 | 5 days | |
25 mg | $614 | 8-10 weeks | |
50 mg | $798 | 8-10 weeks | |
100 mg | $1,360 | 8-10 weeks |
Description | DS-1040 Tosylate is an oral active, selective thrombolytic inhibitor with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa, is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM |
Targets&IC50 | TAFIa (human):5.92 nM , TAFIa (rat):8.01 nM |
In vitro | Ds-1040 Tosylate inhibited human carboxypeptidase N (CPN) in vitro with an IC50 of 3.02 mM. |
In vivo | DS-1040 Tosylate (0.0005-0.5 mg/kg; IV) significantly reduces the microthrombi index at doses of 0.005 mg/kg and greater. DS-1040 (0.016-0.50 mg/kg; i.v.) increases plasma D-dimer levels dose-dependently in a microthrombosis model, with ED50 and EDmax of 122 and 221 nmol/L, respectively. Orally administered DS-1040 (0.25-16 mg/kg) also increases plasma D-dimer levels, with EC50 and ECmax values of 114 and 231 nmol/L, respectively. |
Molecular Weight | 465.61 |
Formula | C23H35N3O5S |
Cas No. | 1335138-89-0 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: 100 mg/mL (214.77 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.